Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
INDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.65 - $58.25
Previous CloseN/A
Volume47.54K
Average Volume (3M)14.98K
Market Cap
$8.58M
Enterprise Value$6.43M
Total Cash (Recent Filing)$6.16M
Total Debt (Recent Filing)$34.37K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 18, 2025EPS Estimate
-4.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.09
Shares Outstanding1,106,529
10 Day Avg. Volume8,105
30 Day Avg. Volume14,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue4.38K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$25.00Price Target Upside236.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe combination study of Decoy and tislelizumab is ongoing, with positive safety results so far, which is promising for the treatment of solid tumors.
Safety ProfileMultiple doses of Decoy20 have shown to be safe and well-tolerated in over 25 patients, indicating a promising safety profile for the therapy.
Strategic PartnershipsIndaptus signed a clinical supply agreement with BeiGene for its PD-1, tislelizumab, which could enhance the study by potentially combining treatments.
Bears Say
Capital RequirementsIndaptus will need to raise additional capital to continue the clinical development of its Decoy immune therapy.
Financial ConcernsThe price target for Indaptus stock has been lowered due to expected dilution from future capital raises and recent financing activities.
Financial HealthIndaptus reported a net loss of ($4.5M) and ended the period with $3.9M in cash on the balance sheet.
Indaptus Therapeutics News
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $6.65 and its highest was $58.25 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Indaptus Therapeutics’s market cap is $8.58M.
When is Indaptus Therapeutics’s upcoming earnings report date?
Indaptus Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 90 days.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on Aug 13, 2025. The company reported -$9.09 earnings per share for the quarter, beating the consensus estimate of -$9.24 by $0.15.
Is Indaptus Therapeutics overvalued?
According to Wall Street analysts Indaptus Therapeutics’s price is currently Undervalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate is -4.17.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 1,106,529 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$9.09 in its last earnings report, beating expectations of -$9.24. Following the earnings report the stock price went up 2.427%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
Company Description
Indaptus Therapeutics
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
INDP Stock 12 Month Forecast
Average Price Target
$25.00
▲(236.93% Upside)
Technical Analysis
Palisade Bio
―
Alaunos Therapeutics
―
Titan Pharmaceuticals
―
Xenetic Biosciences
―
Longevity Health Holdings
―
Ownership Overview
10.13% Insiders
2.09% Mutual Funds
1.32% Other Institutional Investors
84.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---